Search

Your search keyword '"Bahra, M"' showing total 656 results
Start Over Author "Bahra, M"
656 results on '"Bahra, M"'

1. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results

Author

Sinn, M., Liersch, T., Riess, H., Gellert, K., Stübs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J.K., Pelzer, U., Bischoff, S., Bahra, M., and Oettle, H.

Published
2020
Full Text
View/download PDF

4. Neurale Invasion beim Pankreaskarzinom: PlGF als prädiktiver Serummarker und therapeutisches Zielmolekül bei kurativ-intendierter Resektion

Author

Detjen, K., additional, Göhrig, A., additional, Hilfenhaus, G., additional, Rosseck, F., additional, Moser, B., additional, Barbone, G., additional, Kunze, C., additional, Rein, J., additional, Wilken, G. J., additional, Welzel, M., additional, Behm, A., additional, Böhmig, M., additional, Malinka, T., additional, Bahra, M., additional, and Fischer, C., additional

Published
2023
Full Text
View/download PDF

8. Pyloruserhaltende Pankreaskopfresektion

Author

Glanemann, M., Bahra, M., and Neuhaus, P.

Abstract

Zusammenfassung: Die pyloruserhaltende Pankreaskopfresektion nach Traverso-Longmire gilt zur operativen Behandlung von Pankreaskopftumoren als Standardeingriff. Sie ist in Bezug auf Mortalität, Morbidität und onkologische Radikalität als gleichwertig zur klassischen Pankreaskopfresektion nach Kausch-Whipple zu bewerten und zeichnet sich zudem durch kürzere Operationszeit und geringeren Blutverlust aus. Für das Langzeitüberleben ist jedoch nicht die Frage nach Erhalt bzw. Resektion des Magens entscheidend, sondern vielmehr die frühzeitige Diagnosestellung mit nachfolgender R0-Tumorresektion. Patienten profitieren dabei grundlegend von der Behandlung in einem auf Pankreaserkrankungen spezialisierten Zentrum.

Published
2024
Full Text
View/download PDF

9. Independent validation and assay standardization of improved metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis

Author

Mahajan, Ujjwal M., primary, Oehrle, B., additional, Sirtl, S., additional, Alnatsha, A., additional, Goni, E., additional, Regel, I., additional, Beyer, G., additional, Vornhülz, M., additional, Chromik, A., additional, Bahra, M., additional, Klein, F., additional, Uhl, W., additional, Fahlbusch, T., additional, Distler, M., additional, Weitz, J., additional, Grützmann, R., additional, Pilarsky, C., additional, Weiss, F. Ulrich, additional, Adam, G., additional, Kalthoff, H., additional, Rad, R., additional, Christiansen, N., additional, Bethan, B., additional, Kamlage, B., additional, Lerch, M.M., additional, and Mayerle, J., additional

Published
2022
Full Text
View/download PDF

11. Genexpressionsanalyse zur Prognosevorhersage beim duktalen Pankreaskarzinom

Author

Grützmann, R., Wente, M., Niedergethmann, M., Friess, H., Bahra, M., Rümmele, P., Kristiansen, G., Winter, Ch., Saeger, H. D., Pilarsky, Ch., Buhr, H. J., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Post, S., editor, Allgayer, H., editor, Bartsch, D. K., editor, Fries, H., editor, Ghadimi, B. M., editor, Habermann, J. K., editor, Kalthoff, H., editor, Schackert, H. K., editor, Bruns, C. J., editor, Duda, D. N., editor, Fändrich, F., editor, Heberer, M., editor, Nüssler, A. K., editor, Stark, G. B., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Heidecke, C. D., editor, Kalff, J. C., editor, Menger, M. D., editor, Schade, U. F., editor, Vollmar, B., editor, Bechstein, W. O., editor, Klar, E., editor, Klempnauer, J., editor, Minor, T., editor, Neuhaus, P., editor, Schmidt, J., editor, Langer, S., editor, Laschke, M. W., editor, Machens, H. G., editor, Steinau, H. U., editor, Südkamp, N., editor, Vogt, P., editor, Berger, D., editor, Klinge, U., editor, Schachtrupp, A., editor, Schilling, M. K., editor, Schumpelick, V., editor, Altendorf-Hofmann, A., editor, Bollschweiler, E., editor, Bruch, H. -P., editor, Lehnert, T., editor, Lorenz, W., editor, Neugebauer, E., editor, Ohmann, C., editor, Seiler, C. M., editor, Becker, H., editor, Betzler, M., editor, Bittner, R., editor, Broelsch, C., editor, Büchler, M. W., editor, Bumm, R., editor, Dralle, H., editor, Friess, H., editor, Frilling, A., editor, Germer, C. T., editor, Hopt, U., editor, Jonas, S., editor, Jost, J., editor, Markus, B., editor, Raab, H. R., editor, Reith, H. B., editor, Schlag, P. M., editor, Teichmann, W., editor, Uhl, W., editor, Wenisch, H., editor, and Zornig, C., editor

Published
2009
Full Text
View/download PDF

14. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression

Author

Cheung, P.F., Yang, J., Fang, R., Borgers, A., Krengel, K., Stoffel, A., Althoff, K., Yip, C.W., Siu, E.H.L., Ng, L.W.C., Lang, K.S., Cham, L.B., Engel, D.R., Soun, C., Cima, I., Scheffler, B., Striefler, J.K., Sinn, M., Bahra, M., Pelzer, U., Oettle, H., Markus, P., Smeets, E.M.M., Aarntzen, E.H.J.G., Savvatakis, K., Liffers, S.T., Lueong, S.S., Neander, C., Bazarna, A., Zhang, X., Paschen, A., Crawford, H.C., Chan, A.W., Cheung, S.T., Siveke, J.T., Cheung, P.F., Yang, J., Fang, R., Borgers, A., Krengel, K., Stoffel, A., Althoff, K., Yip, C.W., Siu, E.H.L., Ng, L.W.C., Lang, K.S., Cham, L.B., Engel, D.R., Soun, C., Cima, I., Scheffler, B., Striefler, J.K., Sinn, M., Bahra, M., Pelzer, U., Oettle, H., Markus, P., Smeets, E.M.M., Aarntzen, E.H.J.G., Savvatakis, K., Liffers, S.T., Lueong, S.S., Neander, C., Bazarna, A., Zhang, X., Paschen, A., Crawford, H.C., Chan, A.W., Cheung, S.T., and Siveke, J.T.

Abstract

Item does not contain fulltext, Immune evasion is indispensable for cancer initiation and progression, although its underlying mechanisms in pancreatic ductal adenocarcinoma (PDAC) are not fully known. Here, we characterize the function of tumor-derived PGRN in promoting immune evasion in primary PDAC. Tumor- but not macrophage-derived PGRN is associated with poor overall survival in PDAC. Multiplex immunohistochemistry shows low MHC class I (MHCI) expression and lack of CD8(+) T cell infiltration in PGRN-high tumors. Inhibition of PGRN abrogates autophagy-dependent MHCI degradation and restores MHCI expression on PDAC cells. Antibody-based blockade of PGRN in a PDAC mouse model remarkably decelerates tumor initiation and progression. Notably, tumors expressing LCMV-gp33 as a model antigen are sensitized to gp33-TCR transgenic T cell-mediated cytotoxicity upon PGRN blockade. Overall, our study shows a crucial function of tumor-derived PGRN in regulating immunogenicity of primary PDAC.

Published
2022

17. COVID-19 pandemic: implications on the surgical treatment of gastrointestinal and hepatopancreatobiliary tumours in Europe

Author

Nevermann, N F, Hillebrandt, K H, Knitter, S, Ritschl, P V, Krenzien, F, Benzing, C, Bahra, M, Biebl, M, Sauer, I M, Öllinger, R, Schöning, W, Schmelzle, M, Pratschke, J, Abu Hilal, Mohammad, Aldrighetti, Luca, Andersson, Roland, András, Vereczkei, Andreou, Andreas, Arer, İlker Murat, Atıcı, Ali Emre, Szijártó, Attila, Ayav, Ahmet, Aydın, Hüseyin Onur, Bartsch, Detlev, Belli, Andrea, Bertrand, Claude, Bockhorn, Maximilian, Bolli, Martin, Brekalo, Zdrinko, Bruns, Christiane, Ciria, Ruben, Coker, Ahmet, Croner, Roland, dHoore, Andre, Demartines, Nicolas, Demir, Ekin, Dibra, Arvin, Dilek, Osman Nuri, Dogrul, Ahmet, Efanov, Mikhail, Ekmekcigil, Ela, Ergün, Sefa, Farsi, Marco, Fichtner-Feigl, Stefan, Fretland, Åsmund, Friess, Helmut, Beets, Geerard, Gloor, Beat, Gockel, Ines, Gökakın, Ali Kağan, Gomez i Gavara, Concepción, Gretschel, Stephan, Hackl, Christina, Hecker, Andreas, Heinrich, Stefan, Huber, Tobias, Ibis, Cem, Izbicki, Jakob R, Kahlert, Christoph, Kamphues, Carsten, Kapan, Selin, Kazemier, Geert, Kleeff, Joerg, Klink, Christian, Knoefel, Wolfram, Kosieradzki, Maciej, Kube, Rainer, Löb, Stefan, Maagaard Andersen, Lars, Matthaei, Hanno, Mittler, Jens, Morgul, Mehmet Haluk, Moszkowicz, David, Musanovic, Nermin, Nickel, Felix, Nilsson, Magnus, Öfner, Dietmar, Oruğ, Taner, Pascher, Andreas, Pessaux, Patrick, Radionov, Michail, Raraty, Michael, Reissfelder, Christoph, Rhaiem, Rami, Rotellar, Fernando, Ryska, Miroslav, López-Ben, Santiago, Saribeyoglu, Kaya, Schafmayer, Clemens, Schmelzle, Moritz, Schmidt, Thomas, Schneider, Martin, Schoenberg, Markus, Schöning, Wenzel, Seehofer, Daniel, Sönmez, Recep Erçin, Soubrane, Olivier, Stange, Daniel, Strücker, Benjamin, Tursunovic, Amir, Tüzüner, Acar, Vondran, Florian, Weber, Georg, Wellner, Ulrich, Yazici, Pinar, Yeğen, Cumhur, Yol, Sinan, Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), COVID‐19 Surgical Oncology Collaboration Group, Nevermann, N. F., Hillebrandt, K. H., Knitter, S., Ritschl, P. V., Krenzien, F., Benzing, C., Bahra, M., Biebl, M., Sauer, I. M., Ollinger, R., Schoning, W., Schmelzle, M., Pratschke, J., Abu Hilal, M., Aldrighetti, L., Andersson, R., Andras, V., Andreou, A., Arer, I. M., Atici, A. E., Szijarto, A., Ayav, A., Aydin, H. O., Bartsch, D., Belli, A., Bertrand, C., Bockhorn, M., Bolli, M., Brekalo, Z., Bruns, C., Ciria, R., Coker, A., Croner, R., D'Hoore, A., Demartines, N., Demir, E., Dibra, A., Dilek, O. N., Dogrul, A., Efanov, M., Ekmekcigil, E., Ergun, S., Farsi, M., Fichtner-Feigl, S., Fretland, A., Friess, H., Beets, G., Gloor, B., Gockel, I., Gokakin, A. K., Gomez i Gavara, C., Gretschel, S., Hackl, C., Hecker, A., Heinrich, S., Huber, T., Ibis, C., Izbicki, J. R., Kahlert, C., Kamphues, C., Kapan, S., Kazemier, G., Kleeff, J., Klink, C., Knoefel, W., Kosieradzki, M., Kube, R., Lob, S., Maagaard Andersen, L., Matthaei, H., Mittler, J., Morgul, M. H., Moszkowicz, D., Musanovic, N., Nickel, F., Nilsson, M., Ofner, D., Orug, T., Pascher, A., Pessaux, P., Radionov, M., Raraty, M., Reissfelder, C., Rhaiem, R., Rotellar, F., Ryska, M., Lopez-Ben, S., Saribeyoglu, K., Schafmayer, C., Schmidt, T., Schneider, M., Schoenberg, M., Seehofer, D., Sonmez, R. E., Soubrane, O., Stange, D., Strucker, B., Tursunovic, A., Tuzuner, A., Vondran, F., Weber, G., Wellner, U., Yazici, P., Yegen, C., Yol, S., UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service de chirurgie

Subjects
medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, MEDLINE, Surveys and Questionnaires, Correspondence, Pandemic, Humans, Medicine, General, Surgical treatment, Intensive care medicine, Referral and Consultation, Pandemics, Gastrointestinal Neoplasms, SARS-CoV-2, business.industry, Liver Neoplasms, COVID-19, Liver Transplantation, Europe, Pancreatic Neoplasms, Biliary Tract Neoplasms, Surgical Oncology, Italy, Surgical Procedures, Operative, Surgery, Coronavirus Infections, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Published
2020
Full Text
View/download PDF

19. Die Inhibition des Sonic Hedgehog Signalweges im Pankreaskarzinom reduziert das Tumorwachstum in vitro und in vivo

Author

Bahra, M., Neumann, U. P., Jacob, D., Boas-Knoop, S., Koch, A., Buhr, H. J., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Post, S., editor, Allgayer, H., editor, Bartsch, D. K., editor, Fries, H., editor, Ghadimi, B. M., editor, Habermann, J. K., editor, Kalthoff, H., editor, Schackert, H. K., editor, Bruns, C. J., editor, Duda, D. N., editor, Fändrich, F., editor, Heberer, M., editor, Nüssler, A. K., editor, Stark, G. B., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Heidecke, C. D., editor, Kalff, J. C., editor, Menger, M. D., editor, Schade, U. F., editor, Vollmar, B., editor, Bechstein, W. O., editor, Klar, E., editor, Klempnauer, J., editor, Minor, T., editor, Neuhaus, P., editor, Schmidt, J., editor, Langer, S., editor, Laschke, M. W., editor, Machens, H. G., editor, Steinau, H. U., editor, Südkamp, N., editor, Vogt, P., editor, Berger, D., editor, Klinge, U., editor, Schachtrupp, A., editor, Schilling, M. K., editor, Schumpelick, V., editor, Altendorf-Hofmann, A., editor, Bollschweiler, E., editor, Bruch, H. -P., editor, Lehnert, T., editor, Lorenz, W., editor, Neugebauer, E., editor, Ohmann, C., editor, Seiler, C. M., editor, Becker, H., editor, Betzler, M., editor, Bittner, R., editor, Broelsch, C., editor, Büchler, M. W., editor, Bumm, R., editor, Dralle, H., editor, Friess, H., editor, Frilling, A., editor, Germer, C. T., editor, Hopt, U., editor, Jonas, S., editor, Jost, J., editor, Markus, B., editor, Raab, H. R., editor, Reith, H. B., editor, Schlag, P. M., editor, Teichmann, W., editor, Uhl, W., editor, Wenisch, H., editor, and Zornig, C., editor

Published
2009
Full Text
View/download PDF

48. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine plus sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results

Author

Sinn, M., Liersch, T., Riess, H., Gellert, K., Stuebs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J. K., Pelzer, U., Bischoff, S., Bahra, M., Oettle, H., Sinn, M., Liersch, T., Riess, H., Gellert, K., Stuebs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J. K., Pelzer, U., Bischoff, S., Bahra, M., and Oettle, H.

Abstract

Background: CONKO-006 was designed for patients with pancreatic adenocarcinoma with postsurgical R1 residual status to evaluate the efficacy and safety of the combination of gemcitabine and sorafenib (GemSorafenib) compared with those of gemcitabine + placebo (GemP) for 12 cycles. Patients and methods: This randomised, double-blind, placebo-controlled, multicenter study was planned to detect an improvement in recurrence-free survival (RFS) from 42% to 60% after 18 months. Secondary objectives were overall survival (OS), safety and duration of treatment. Results: 122 patients were included between 02/2008 and 09/2013; 57 were randomised to GemSorafenib and 65 to GemP. Patient characteristics were wellbalanced (GemSorafenib/GemP) in terms of median age (63/63 years), tumour size (T3/T4: 97/97%), and nodal positivity (86/85%). Grade 3/4 toxicities comprised diarrhoea (GemSorafenib: 12%; GemP: 2%), elevated gamma-glutamyl transferase (GGT) (19%; 9%), fatigue (5%; 2%) and hypertension (5%; 2%), as well as neutropenia (18%; 25%) and thrombocytopenia (9%; 2%). By August 2017, 118 (97%) RFS event had occurred. There were no difference in RFS (median GemSorafenib: 8.5 versus GemP: 9.4 months; p = 0.730) nor OS (median GemSorafenib: 17.6 versus GemP: 17.5 months; p = 0.481). Landmark analyses suggest that patients who received more than six cycles of postoperative chemotherapy had significantly longer OS (p = 0.021). Conclusion: CONKO-006 is the first randomised clinical trial to include exclusively patients with PDAC with postsurgical R1 status thus far. Sorafenib added to gemcitabine did neither improve RFS nor OS. However, postoperative treatment exceeding six months seemed to prolong survival and should be further investigated in these high-risk patients. (C) 2020 Published by Elsevier Ltd.

Published
2020

49. COVID-19 pandemic: implications on the surgical treatment of gastrointestinal and hepatopancreatobiliary tumours in Europe.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, Nevermann, N F, Hillebrandt, K H, Knitter, S, Ritschl, P V, Krenzien, F, Benzing, C, Bahra, M, Biebl, M, Sauer, I M, Öllinger, R, Schöning, W, Schmelzle, M, Pratschke, J, COVID-19 Surgical Oncology Collaboration Group, Bertrand, Claude, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, Nevermann, N F, Hillebrandt, K H, Knitter, S, Ritschl, P V, Krenzien, F, Benzing, C, Bahra, M, Biebl, M, Sauer, I M, Öllinger, R, Schöning, W, Schmelzle, M, Pratschke, J, COVID-19 Surgical Oncology Collaboration Group, and Bertrand, Claude

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results